CELL INTELLIGENCE · 肿瘤细胞治疗研究

通过 mRNA-LNP 工程化 CLL-1 CAR-NK 细胞以获得强效抗肿瘤活性并逆转急性髓系白血病中 HLA-E 介导的耐药

Engineering CLL-1 CAR-NK cells via mRNA-LNP for potent antitumor activity and reversal of HLA-E-mediated resistance in acute myeloid leukemia.

瞬时、非整合的 mRNA LNP 转染的 CLL-1 CAR-NK 细胞为 MDR AML 提供了一种安全有效的策略。

基于 CircRNA 的 CD19 靶向 CAR-NK 疗法用于 B 细胞急性淋巴细胞白血病，采用粗球孢子菌来源的 II 组内含子平台

CircRNA-based CD19-targeted CAR-NK therapy for B-cell acute lymphoblastic Leukemia using a Coccidioides immitis-derived group II intron platform.

BNT162b2 mRNA 疫苗接种影响滤泡性淋巴瘤和慢性淋巴细胞白血病患者的肠道微生物组组成

BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia.

泛素特异性蛋白酶 6 mRNA 脂质纳米颗粒在尤文肉瘤中激发抗肿瘤免疫并抑制肿瘤发生

Ubiquitin-Specific Protease 6 mRNA Lipid Nanoparticles Ignite Antitumor Immunity and Suppress Tumorigenesis in Ewing Sarcoma.

脂质纳米颗粒介导抗 CD19 CAR mRNA 递送至脐带血 NK 细胞以靶向 CD19⁺ 原代 B-ALL 细胞

Lipid nanoparticle mediated delivery of Anti-CD19 CAR mRNA to umbilical cord blood NK cells for targeting CD19⁺ primary B-ALL cells.

接受异基因干细胞移植治疗髓系恶性肿瘤的患者对 COVID-19 mRNA 疫苗的特异性免疫应答受到免疫抑制治疗的改变

Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was alter

结果显示，HSCT 受者对 SARS-CoV-2 疫苗的体液和细胞适应性免疫应答均受到皮质类固醇治疗的显著抑制。对疫苗的特异性应答受到 HSCT 与接种疫苗之间间隔时间的显著影响。HSCT 后最早 5 个月接种疫苗即可产生良好应答。对疫苗的免疫应答与年龄、性别、HSC 供受者之间的 HLA 匹配或髓系恶性肿瘤类型无关。疫苗效力取决于 HSCT 后 6 个月时重建良好的 CD4 + T 细胞。